

**Radhika Deshpande, MBBS**

Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL

**Yasser Al Khadra, MD**

Department of Medicine, Division of Cardiology, Southern Illinois University School of Medicine, Springfield, IL

**Raad Al-Tamimi, MBBS**

Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL



BRIEF  
ANSWERS  
TO SPECIFIC  
CLINICAL  
QUESTIONS

**Nour Albast, MBBS**

Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL

**Mohamed Labedi, MD**

Assistant Professor, Department of Medicine, Division of Cardiology, Southern Illinois University School of Medicine, Springfield, IL

# Q: Atrial fibrillation: Rate control or rhythm control?

**A:** ATRIAL FIBRILLATION CAN BE MANAGED by either a rate control or a rhythm control strategy. Data as to which provides better clinical outcomes have been mixed.

Until now, rate control has been preferred, in view of the side effects of antiarrhythmic drugs and the noninferiority of rate control that was demonstrated in multiple studies.<sup>1-4</sup> However, rate control as the primary approach is now in question, and the pendulum is swinging in favor of rhythm control.

For patients with atrial fibrillation, the 3 principal goals of therapy are to control symptoms, prevent thromboembolism and stroke, and prevent tachycardia-mediated cardiomyopathy.<sup>5</sup> Maintaining sinus rhythm has many benefits, as it is more physiologic and maintains atrioventricular synchronicity with improved ventricular filling through “atrial kick,” thereby improving exercise tolerance, relieving symptoms better, and preventing structural and electrical remodeling.<sup>6</sup> Therefore, even if direct evidence from randomized clinical trials is lacking in many types of patients, given the unpredictable long-term adverse effects of atrial fibrillation, rhythm control is generally the goal. Another factor pushing us in that direction is modern technology such as pulsed-field ablation, which has shown benefits and safety in preclinical and clinical studies.<sup>7</sup>

## ■ EVIDENCE FAVORING RATE CONTROL

Several landmark trials formed the basis of current guidelines for treating atrial fibrillation.<sup>8</sup>

**The AFFIRM trial** (Atrial Fibrillation Follow-up Investigation of Rhythm Management),<sup>1</sup> published in 2002, was one of the first large randomized controlled trials to compare rate control and rhythm control.

doi:10.3949/ccjm.89a.21093

It found no difference in survival outcomes between the strategies, and rates of hospitalization and adverse drug effects were significantly lower with rate control. In both study groups, most strokes occurred after warfarin was stopped or when the international normalized ratio was subtherapeutic. The mean age of the patients was 70, and therefore these results may not be applicable to younger patients.

**Up to now, rate control has been preferred, but the pendulum is swinging in favor of rhythm control**

**The STAF study** (Strategies of Treatment of Atrial Fibrillation)<sup>2</sup> yielded results similar to those of the AFFIRM trial in terms of both survival and hospitalizations.

**The PIAF trial** (Pharmacological Intervention in Atrial Fibrillation)<sup>3</sup> showed no significant difference in symptom improvement between the treatment groups, but the rhythm control group had more hospital admissions.

**The RACE study** (Rate Control vs Electrical Cardioversion for Persistent Atrial Fibrillation)<sup>4</sup> found more cardiovascular deaths and hospitalizations for congestive heart failure with rate control, while thromboembolic events, drug side effects, and pacemaker implantation were more frequent in the rhythm control group.

Of note, most of these trials were designed to evaluate the *noninferiority* of rate control compared with rhythm control, not *superiority*. Another consideration is that these trials were conducted almost 20 years ago, and rhythm control strategies—in particular, ablation—have since evolved.

**TABLE 1**  
**Treatments for atrial fibrillation**

| Treatment   | Indications  | Contraindications   |
|---|--|---|
| <b>Rate control</b>   | Asymptomatic atrial fibrillation and rhythm control not favored (elderly patient, long-standing atrial fibrillation, markedly enlarged left atrium)  | Avoid calcium channel blockers in patients with heart failure   |
| <b>Electric cardioversion</b>   | Symptomatic atrial fibrillation<br>New-onset atrial fibrillation<br>Low risk of thromboembolism:<br>( $< 48$ hours since onset of atrial fibrillation, or at least 3 weeks of anticoagulation, or transesophageal echocardiography to rule out thrombus) | No anticoagulation or inability to obtain transesophageal echocardiography  |
| <b>Antiarrhythmic medications</b>   | Younger patient<br>High cardiovascular risk<br>Heart failure<br>Failure of rate control therapy  | Avoid propafenone and flecainide in those with structural heart disease and coronary heart disease<br>Avoid dronedarone in persistent atrial fibrillation and congestive heart failure<br>Avoid sotalol and dofetilide in renal failure |
| <b>Catheter ablation</b>  | Younger patients<br>Symptomatic atrial fibrillation, refractory to medical therapy<br>Can be considered in heart failure   | Marked left atrial dilation   |
| <b>Atrioventricular junction ablation and cardiac resynchronization therapy</b> | Contraindication to ablation or failure of ablation<br>Permanent atrial fibrillation<br>Systolic heart failure with ejection fraction $< 30\%$   | Frail patient<br>Expected survival $< 1$ year   |

**EVIDENCE FAVORING RHYTHM CONTROL**

Rhythm control strategies include antiarrhythmic drug therapy and catheter ablation.

The EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial)<sup>9</sup> reported that in patients with a diagnosis of atrial fibrillation within the past year and concomitant high-cardiovascular-risk conditions, treatment with drugs or catheter ablation was associated with lower risks of death from cardiovascular causes, stroke, or hospitalization for heart failure or acute coronary syndrome than usual care. Furthermore, there was no significant difference in length of hospital stay between the groups. The favorable results for rhythm control were likely due to including catheter ablation along with antiarrhythmic drugs as a rhythm control treatment.

**The Get With The Guidelines—Heart Failure**

registry<sup>10</sup> study found that rhythm control was associated with lower risk of death at 1 year in patients age 65 and older with atrial fibrillation and heart failure with preserved ejection fraction.

Shojaee et al<sup>11</sup> found that, in patients who presented to the emergency department in rapid atrial fibrillation, amiodarone was superior to digoxin with regard to treatment success and quicker onset of action.

Delle Karth et al<sup>12</sup> compared amiodarone vs diltiazem in critically ill patients and found equivalent outcomes with either drug. However, more patients had to discontinue diltiazem therapy due to hypotension.

**EVIDENCE ON CATHETER ABLATION VS MEDICAL THERAPY**

Numerous randomized controlled trials have compared catheter ablation and medical therapy for

rhythm control in atrial fibrillation.

The **CASTLE-AF** (Catheter Ablation for Atrial Fibrillation With Heart Failure)<sup>13</sup> and **AATAC** (Ablation vs Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device)<sup>14</sup> trials included patients with atrial fibrillation and left ventricular systolic dysfunction. They showed that catheter ablation was associated with significantly lower rates of death from any cause or of hospitalization for worsening heart failure compared with medical therapy. CASTLE-AF compared catheter ablation vs medical therapy for rate or rhythm control, whereas AATAC compared catheter ablation vs amiodarone.

The **CABANA trial** (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation)<sup>15</sup> included patients with and without left ventricular systolic dysfunction and an overall healthier cohort than in CASTLE-AF and AATAC. Catheter ablation did not show a significant reduction in death, disabling stroke, serious bleeding, or cardiac arrest compared with medical therapy at 12 months. These results were thought to be affected by lower-than-expected event rates and high crossover rates in the study. Per-protocol analyses, as opposed to intention-to-treat analyses, showed significant benefit with catheter ablation vs drug therapy with regard to both the primary and secondary end points. On subgroup analysis, the maximal benefit of catheter ablation was in younger patients.<sup>16</sup>

**D'Angelo et al**<sup>17</sup> performed a retrospective study and found results comparable to those of CABANA, with early referral for catheter ablation showing better outcomes as opposed to late referral.

The **STOP-AF First**<sup>18</sup> and **EARLY-AF** (Early Aggressive Invasive Intervention for Atrial Fibrillation)<sup>19</sup> trials found lower rates of recurrence of arrhythmia with cryoablation than with antiarrhythmic drug therapy.

**Asad et al**<sup>20</sup> performed a meta-analysis of the above-mentioned studies and several others comparing catheter ablation vs medical therapy for atrial fibrillation. The rate of all-cause mortality was lower with catheter ablation, a difference that was primarily driven by patients with atrial fibrillation and heart failure with reduced ejection fraction from the CASTLE-AF trial. Moreover, there were significant reductions in cardiovascular hospitalizations and recurrence of atrial arrhythmia with catheter ablation in patients both with and without heart failure.

## INDIVIDUALIZED THERAPY

The choice of therapy should be individualized, as summarized in (Table 1).

**Rate control** with a beta-blocker or calcium channel blocker may be preferred in patients with asymptomatic atrial fibrillation (whether paroxysmal, persistent, or permanent) and in patients in whom rhythm control may not be a good option, such as elderly patients, patients with long-standing atrial fibrillation, and those with markedly enlarged left atria. Calcium channel blockers are best avoided in patients with heart failure.

**Since its invention, ablation  
has demonstrated the best outcomes  
with regard to mortality and morbidity**

### Rhythm control

Rhythm control may be preferable in patients who are younger, are at high cardiovascular risk, or have heart failure, or in patients for whom rate-control therapy has failed.

**Cardioversion** can restore sinus rhythm and can be repeated multiple times if unsuccessful at first. It can be used for patients with symptoms or with newly diagnosed atrial fibrillation. To lessen the risk of thromboembolism, patients must have had atrial fibrillation for less than 48 hours, must have been on anticoagulation for at least 3 weeks, or must undergo transesophageal echocardiography to rule out thrombus before cardioversion.<sup>21</sup>

**Antiarrhythmic drug therapy.** Occasionally, certain antiarrhythmic drugs may need to be started in the hospital to ensure patient safety, as they can lead to life-threatening arrhythmias. Amiodarone and dronedarone have the least-cardiotoxic adverse effects compared with other antiarrhythmic drugs. However, amiodarone has significant systemic effects, including liver, lung, and thyroid toxicity. Dronedarone has a better systemic adverse-effect profile than amiodarone, but it is associated with hepatotoxicity.

Dronedarone cannot be used in patients with heart failure, as a higher mortality rate has been reported in this subgroup when given dronedarone.<sup>22</sup> Moreover, the **PALLAS study** (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy)<sup>23</sup> found that dronedarone was associated with higher rates of stroke, cardiovascular death, and readmission when used to treat permanent atrial fibrillation.

Amiodarone is the most commonly prescribed antiarrhythmic drug for atrial fibrillation, and when compared with other antiarrhythmics, including sotalol, dronedarone, propafenone, and flecainide, it was the most effective in maintaining sinus rhythm.<sup>24-27</sup>

Amiodarone, sotalol, and dofetilide can be safely used in patients with structural heart disease, but caution is advised for other antiarrhythmic drugs.

Propafenone and flecainide are good options in patients without structural heart disease.<sup>28</sup>

**Catheter ablation.** Since its invention, ablation has demonstrated the best outcomes with regard to mortality and morbidity. Trials that compared catheter ablation and drug therapy (for rate control or rhythm control) have consistently shown better outcomes with catheter ablation. It is a good option for patients who are younger, do not have left atrial dilation, have symptomatic atrial fibrillation, or have atrial fibrillation that is refractory to medical ther-

apy.<sup>29,30</sup> It can be considered for patients who have heart failure and for those who have no symptoms, after shared decision-making.<sup>31</sup>

**Ablate and pace.** In cases in which atrial fibrillation persists despite multiple ablations or regular ablation is contraindicated, a possible next step is atrioventricular junction ablation with cardiac resynchronization therapy—ie, destroying the electrical link between the left atrium and left ventricle and putting in a pacemaker. Patients who underwent this “ablate-and-pace” procedure had a lower mortality rate than those who received control therapy in the APAF-CRT (Ablate and Pace for Atrial Fibrillation—Cardiac Resynchronization Therapy) trial.<sup>32</sup> ■

## DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

## REFERENCES

1. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347(23):1825–1833. doi:10.1056/NEJMoa021328
2. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. *J Am Coll Cardiol* 2003; 41(10):1690–1696. doi:10.1016/s0735-1097(03)00332-2
3. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. *Lancet* 2000; 356(9244):1789–1794. doi:10.1016/s0140-6736(00)03230-x
4. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the Rate Control vs Electrical Cardioversion (RACE) study. *Am Heart J* 2005; 149(6): 1106–1111. doi:10.1016/j.ahj.2004.11.030
5. Zimetbaum P. Atrial fibrillation. *Ann Intern Med* 2017; 166(5): ITC33–ITC48. doi:10.7326/AITC201703070
6. Wijffels MC, Crijns HJ. Rate versus rhythm control in atrial fibrillation. *Cardiol Clin* 2004; 22(1):63–69. doi:10.1016/s0733-8651(03)00112-7
7. Maan A, Koruth J. Pulsed field ablation: a new paradigm for catheter ablation of arrhythmias. *Curr Cardiol Rep* 2022; 24(2):103–108. doi:10.1007/s11886-021-01630-z
8. Frost JL, Campos-Outcalt D, Hoelting D, et al. Updated clinical practice guideline. Pharmacologic management of newly detected atrial fibrillation. American Academy of Family Physicians, 2017. Available at: [https://www.aafp.org/dam/AAFP/documents/patient\\_care/clinical\\_recommendations/a-fib-guideline.pdf](https://www.aafp.org/dam/AAFP/documents/patient_care/clinical_recommendations/a-fib-guideline.pdf). Accessed September 1, 2022.
9. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med* 2020; 383(14): 1305–1316. doi:10.1056/NEJMoa2019422
10. Kelly JP, DeVore AD, Wu J, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from Get with the Guidelines—Heart Failure. *J Am Heart Assoc* 2019; 8(24):e011560. doi:10.1161/JAHA.118.011560
11. Shojaaee M, Feizi B, Miri R, Etemadi J, Feizi AH. Intravenous amiodarone vs digoxin in atrial fibrillation rate control; a clinical trial. *Emerg (Tehran)* 2017; 5(1):e29. PMID:28286836
12. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. *Crit Care Med* 2001; 29(6):1149–1153. doi:10.1097/00003246-200106000-00011
13. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med* 2018; 378(5):417–427. doi:10.1056/NEJMoa1707855
14. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. *Circulation* 2016; 133(17):1637–1644. doi:10.1161/CIRCULATIONAHA.115.019406
15. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA* 2019; 321(13):1261–1274. doi:10.1001/jama.2019.0693
16. Bahnon TD, Giczewska A, Mark DB, et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: results from the CABANA trial. *Circulation* 2022; 145(11):796–804. doi:10.1161/CIRCULATIONAHA.121.055297
17. D’Angelo RN, Khanna R, Wong C, et al. Very early versus early referral for ablation in young patients with newly diagnosed paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol* 2022; 45(3):348–356. doi:10.1111/pace.14459
18. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. *N Engl J Med* 2021; 384(4): 316–324. doi:10.1056/NEJMoa2029554
19. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. *N Engl J Med* 2021; 384(4):305–315. doi:10.1056/NEJMoa2029980
20. Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter ablation versus medical therapy for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. *Circ Arrhythm Electrophysiol* 2019; 12(9):e007414. doi:10.1161/CIRCEP.119.007414
21. Kim SS, Knight BP. Electrical and pharmacologic cardioversion for atrial fibrillation. *Cardiol Clin* 2009; 27(1):95–ix. doi:10.1016/j.ccl.2008.09.008
22. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. *N Engl J Med*

- 2008; 358(25):2678–2687. doi:10.1056/NEJMoa0800456
23. **Connolly SJ, Camm AJ, Halperin JL, et al.** Dronedaronone in high-risk permanent atrial fibrillation. *N Engl J Med* 2011; 365(24):2268–2276. doi:10.1056/NEJMoa1109867
  24. **Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M.** Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. *Europace* 2011; 13(3):329–345. doi:10.1093/europace/euq450
  25. **Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM.** A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. *J Cardiovasc Electrophysiol* 2010; 21(6):597–605. doi:10.1111/j.1540-8167.2010.01764.x
  26. **Roy D, Talajic M, Dorian P, et al.** Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. *N Engl J Med* 2000; 342(13):913–920. doi:10.1056/NEJM200003303421302
  27. **Singh BN, Singh SN, Reda DJ, et al.** Amiodarone versus sotalol for atrial fibrillation. *N Engl J Med* 2005; 352(18):1861–1872. doi:10.1056/NEJMoa041705
  28. **Zimetbaum P.** Antiarrhythmic drug therapy for atrial fibrillation. *Circulation* 2012; 125(2):381–389. doi:10.1161/CIRCULATIONAHA.111.019927
  29. **Mujović N, Marinković M, Lenarczyk R, Tilz R, Potpara TS.** Catheter ablation of atrial fibrillation: an overview for clinicians. *Adv Ther* 2017; 34(8):1897–1917. doi:10.1007/s12325-017-0590-z
  30. **Zimetbaum P.** Is rate control or rhythm control preferable in patients with atrial fibrillation? An argument for maintenance of sinus rhythm in patients with atrial fibrillation. *Circulation* 2005; 111(23):3150–3157. doi:10.1161/CIRCULATIONAHA.104.537175
  31. **Parameswaran R, Al-Kaisey AM, Kalman JM.** Catheter ablation for atrial fibrillation: current indications and evolving technologies. *Nat Rev Cardiol* 2021; 18(3):210–225. doi:10.1038/s41569-020-00451-x
  32. **Brignole M, Pentimalli F, Palmisano P, et al.** AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. *Eur Heart J* 2021; 42(46):4731–4739. doi:10.1093/eurheartj/ehab569
- .....  
*Address: Radhika Deshpande, MBBS, Southern Illinois University School of Medicine, 701 N 1st Street, Springfield, IL 62704; radhik.deshpande@gmail.com*